Published in Oncogene on June 16, 2014
Defined culture of human embryonic stem cells and xeno-free derivation of retinal pigmented epithelial cells on a novel, synthetic substrate. Stem Cells Transl Med (2015) 0.90
Oncometabolic Nuclear Reprogramming of Cancer Stemness. Stem Cell Reports (2016) 0.83
Metabolic control of cancer cell stemness: Lessons from iPS cells. Cell Cycle (2015) 0.81
Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma. Oncotarget (2015) 0.80
Senescence-Inflammatory Regulation of Reparative Cellular Reprogramming in Aging and Cancer. Front Cell Dev Biol (2017) 0.80
Repressors of reprogramming. World J Stem Cells (2015) 0.75
Advances and Challenges on Cancer Cells Reprogramming Using Induced Pluripotent Stem Cells Technologies. J Cancer (2016) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
The hallmarks of cancer. Cell (2000) 113.05
Chromatin modifications and their function. Cell (2007) 55.98
Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science (2009) 32.97
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63
The epigenomics of cancer. Cell (2007) 30.91
Establishment in culture of pluripotential cells from mouse embryos. Nature (1981) 30.49
Control of developmental regulators by Polycomb in human embryonic stem cells. Cell (2006) 28.21
Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature (2006) 25.90
DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell (1999) 25.75
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell (2004) 21.30
The ground state of embryonic stem cell self-renewal. Nature (2008) 19.44
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Epigenetics in cancer. N Engl J Med (2008) 17.36
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
DNMT3A mutations in acute myeloid leukemia. N Engl J Med (2010) 14.07
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
The Polycomb group protein EZH2 directly controls DNA methylation. Nature (2005) 13.67
Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet (2009) 12.08
Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer (2006) 11.48
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet (2007) 9.88
Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell (2005) 9.84
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature (2011) 9.71
Cancer stem cells. N Engl J Med (2006) 9.63
Epigenetic stem cell signature in cancer. Nat Genet (2006) 9.62
Active DNA demethylation: many roads lead to Rome. Nat Rev Mol Cell Biol (2010) 9.35
Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature (1983) 9.28
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature (2010) 8.87
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature (2005) 8.53
Regulation of chromatin by histone modifications. Cell Res (2011) 8.44
MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer (2007) 8.17
MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell (2002) 8.17
Cancer stem cells: models and concepts. Annu Rev Med (2007) 8.06
Stem cells and cancer; the polycomb connection. Cell (2004) 7.43
Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell (2011) 7.41
Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet (2010) 7.39
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell (2011) 7.37
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature (2012) 7.01
EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell (2008) 6.86
The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature (2011) 6.73
DNA methylation: roles in mammalian development. Nat Rev Genet (2013) 6.65
Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol Cell (2005) 6.29
Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev (1994) 6.10
Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nat Struct Mol Biol (2006) 6.03
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell (2009) 5.81
Maintenance of self-renewal ability of mouse embryonic stem cells in the absence of DNA methyltransferases Dnmt1, Dnmt3a and Dnmt3b. Genes Cells (2006) 5.68
Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev (1999) 5.35
Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. Mol Cell Biol (2003) 5.27
Cancer stem cells: mirage or reality? Nat Med (2009) 5.20
Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet (2008) 5.08
The SWI/SNF complex and cancer. Oncogene (2009) 5.05
Epigenetic reprogramming and induced pluripotency. Development (2009) 4.90
Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev (2003) 4.71
Myc influences global chromatin structure. EMBO J (2006) 4.71
The SWI/SNF complex--chromatin and cancer. Nat Rev Cancer (2004) 4.59
Cancer stem cells: an evolving concept. Nat Rev Cancer (2012) 4.57
The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat Genet (2008) 4.40
Chromatin-modifying enzymes as modulators of reprogramming. Nature (2012) 4.22
Self-renewal as a therapeutic target in human colorectal cancer. Nat Med (2013) 4.20
Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell (2010) 4.18
Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature (2007) 4.12
Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol (2010) 4.04
Wdr5 mediates self-renewal and reprogramming via the embryonic stem cell core transcriptional network. Cell (2011) 4.04
Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell (2012) 4.04
Rethinking how DNA methylation patterns are maintained. Nat Rev Genet (2009) 4.03
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol (2012) 3.89
An embryonic stem cell chromatin remodeling complex, esBAF, is essential for embryonic stem cell self-renewal and pluripotency. Proc Natl Acad Sci U S A (2009) 3.82
Enhancer decommissioning by LSD1 during embryonic stem cell differentiation. Nature (2012) 3.67
Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell (2012) 3.65
Epigenetic signatures of stem-cell identity. Nat Rev Genet (2007) 3.56
Epigenetic reprogramming in cancer. Science (2013) 3.47
The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer (2011) 3.42
DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet (2002) 3.25
Chromatin remodelling in mammalian differentiation: lessons from ATP-dependent remodellers. Nat Rev Genet (2006) 3.12
Chromatin-Remodeling Components of the BAF Complex Facilitate Reprogramming. Cell (2010) 3.08
Chromatin connections to pluripotency and cellular reprogramming. Cell (2011) 3.07
MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell (2013) 2.92
Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation. Cell (2014) 2.82
Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene (2012) 2.82
FGF signaling inhibition in ESCs drives rapid genome-wide demethylation to the epigenetic ground state of pluripotency. Cell Stem Cell (2013) 2.79
EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res (2009) 2.68
Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res (2009) 2.65
Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2. Nature (2012) 2.64
NANOG-dependent function of TET1 and TET2 in establishment of pluripotency. Nature (2013) 2.63
Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res (2006) 2.62
Trithorax group proteins: switching genes on and keeping them active. Nat Rev Mol Cell Biol (2011) 2.56
EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell (2011) 2.54
Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis (2009) 2.54
Naive pluripotency is associated with global DNA hypomethylation. Nat Struct Mol Biol (2013) 2.49
Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells (2009) 2.48
Spontaneous Testicular Teratomas in an Inbred Strain of Mice. Proc Natl Acad Sci U S A (1954) 2.47
c-Myc is required for maintenance of glioma cancer stem cells. PLoS One (2008) 2.41
Hypomethylation of ras oncogenes in primary human cancers. Biochem Biophys Res Commun (1983) 2.41
The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell (2013) 2.33
Whole-genome bisulfite sequencing of two distinct interconvertible DNA methylomes of mouse embryonic stem cells. Cell Stem Cell (2013) 2.32